No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
US OptionsDetailed Quotes
JNJ241220P155000
- 10.25
- +1.77+20.87%
15min DelayClose Dec 16 16:00 ET
10.40High9.40Low
9.40Open8.48Pre Close1.36K Volume665 Open Interest155.00Strike Price1.40MTurnover0.00%IV-0.63%PremiumDec 20, 2024Expiry Date11.15Intrinsic Value100Multiplier4DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma13.64Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Intraday
- 5D
- Daily
News
Express News | J&J - Currently Approved Intravenous Formulation of Rybrevant (Amivantamab-Vmjw) Is Not Impacted by Crl
Express News | J&J - FDA Issued Crl for Bla for Combination of Amivantamab & Recombinant Human Hyaluronidase for Subcutaneous Amivantamab
Dow's 111-Point Drop Led By Losses For UnitedHealth, Verizon Shares
Moderna Remains the Most Shorted Among S&P 500 Healthcare Stocks in November
Express News | J&J: Submits Application Seeking U.S. FDA Approval of Simponi® (Golimumab) for Treatment of Pediatric Ulcerative Colitis
Johnson & Johnson is suing a division of Cigna, accusing it of misappropriating a financial aid fund.
On December 16, Gleno Exchange reported that Johnson & Johnson has filed a lawsuit against a division of Cigna, accusing the medical insurance company of collaborating with pharmaceutical benefit managers to steal Johnson & Johnson's financial assistance funds, which are specifically designated for patients using some of Johnson & Johnson's high stock price drugs.